CellSource Co., Ltd.

Equities

4880

JP3423580004

Healthcare Facilities & Services

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
1,522 ^JPY	+0.33%		+3.75%	+19.00%

2023	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	CI
2023	MEDERI Inc. announced that it has received funding from CellSource Co., Ltd.	CI

CellSource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023

December 14, 2022 at 01:00 am EST

CellSource Co., Ltd. provided non-consolidated earnings guidance for the Fiscal Year Ending October 31, 2023. For the year, the company expects net sales of JPY 5,192 million, Operating profit of JPY 1,625 million, Profit of JPY 1,024 million or Basic EPS of JPY 54.81.

Latest news about CellSource Co., Ltd.

Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	Dec. 22	CI
MEDERI Inc. announced that it has received funding from CellSource Co., Ltd.	Nov. 01	CI
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023.	23-09-23	CI
Cuorips Inc. has completed an IPO in the amount of Â¥3.432 billion.	23-06-27	CI
Cellsource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023	23-06-14	CI
Cellsource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023	23-03-14	CI
CellSource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023	22-12-14	CI
Lumirous Sdn Bhd announced that it has received funding from CellSource Co., Ltd.	22-02-23	CI
Cuorips Inc. announced that it has received ¥1.6 billion in funding from JIC Venture Growth Investments Co., Ltd., JAFCO Group Co., Ltd., Osaka University Venture Capital Co., Ltd., Fujifilm Corporation, CellSource Co., Ltd., Kyoto-University-Venture NVCC No.2 Investment Limited Partnership	21-03-14	CI
CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd	21-02-15	CI
CellSource Co., Ltd.(TSE:4880) added to S&P Global BMI Index	20-09-21	CI
Certain Common Stock of CellSource Co., Ltd. are subject to a Lock-Up Agreement Ending on 24-APR-2020.	20-04-23	CI
CellSource Co., Ltd. has completed an IPO in the amount of ¥1.0944 billion.	19-10-27	CI
CellSource Co., Ltd. has filed an IPO.	19-09-19	CI

Chart CellSource Co., Ltd.

Duration

Period

More charts

Company Profile

CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.

Sector

Healthcare Facilities & Services

Calendar

2024-06-09 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CellSource Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
CELLSOURCE CO., LTD.	+19.00%	191M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories